Diceros’ drug candidate, Verasone™, is a proprietary, patent-protected combination of two existing therapies that will be used for the treatment of chronic rhinosinusitis (CRS). Diceros believes Verasone’s evidence-based dual mechanism of action will make it superior to existing treatments by providing improved clinical efficacy while reducing side effects.  It will be administered by high-volume sinonasal irrigation which has been proven to be one of the most effective ways to administer topical drugs for the treatment of CRS. Verasone™ is currently undergoing clinical trials.